Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 and based in Copenhagen, Denmark. The firm has established itself as a significant player in the Nordic venture capital scene, particularly in the life sciences sector. With approximately €500 million under management across 19 funds, Sunstone focuses on early-stage drug development, aiming to transform scientific discoveries into products that enhance patient outcomes and create value for innovators, investors, and healthcare systems globally.
Over the years, Sunstone has built a diverse portfolio, having invested in 201 companies, with a notable emphasis on life science therapeutics. The firm operates from its office in Frederiksberg, Denmark, and collaborates with a range of institutional investors and co-investors to support its portfolio companies. Sunstone's commitment to addressing unmet medical needs, particularly in oncology and specialty pharmaceuticals, has positioned it as a key partner for startups in the life sciences domain.
Sunstone Life Science Ventures primarily invests in early-stage life science companies that are developing novel therapeutics for humans. The firm typically engages in investments during the pre-clinical or clinical phase I stages, focusing on opportunities that address unmet medical needs. Sunstone's investment strategy emphasizes niche markets, particularly specialty pharmaceuticals and orphan drug indications, with a strong interest in oncology.
The firm targets investments in Europe, particularly in the UK and other prominent life science hubs. Sunstone seeks companies with solid in-vivo preclinical data and a well-understood mechanism of action, typically entering at the Series A and B funding stages. This approach allows Sunstone to support companies that are pioneering advancements in healthcare and improving patient outcomes.
Sunstone Life Science Ventures has invested in over 45 life science companies, with a diverse portfolio that includes:
These companies represent Sunstone's commitment to investing in innovative solutions that address critical healthcare challenges.
Søren Lemonius: Managing General Partner with extensive experience in venture capital and life sciences.
Peter Benson: Chairman & General Partner, a founding partner with a strong background in life sciences investments.
Dr. Sten Verland: General Partner with expertise in drug development and investment strategies.
Dr. Claus Andersson: General Partner, focusing on early-stage investments in life sciences.
Line Jacobsen: Management Assistant supporting the operational aspects of the firm.
Søren Rask Tange: Finance Director overseeing financial operations.
Merete Lundbye Møller: Venture Partner and General Counsel, providing legal insights and support.
Sten Verland: Venture Partner with a focus on strategic investments.
Robert Cobuzzi: Venture Partner with a background in life sciences.
Stephanie Munk: Investment Director involved in sourcing and evaluating investment opportunities.
Kartik Kashyap: Student Assistant contributing to research and analysis.
Sophie Blomgren-Hansen: Student Assistant supporting various projects within the firm.
Startups interested in pitching to Sunstone Life Science Ventures should reach out via email at lifescience@sunstone.eu. It is recommended to include a comprehensive pitch deck that outlines the company's mission, product development stage, market opportunity, and any relevant clinical data. Response times may vary, so founders should be prepared for potential follow-up discussions.
In early 2026, Sunstone Life Science Ventures has been actively sharing insights through blog posts on topics such as biotech venture capital investing, M&A returns, and the impact of local investors on the ecosystem. These publications reflect the firm's ongoing engagement with industry trends and challenges.
Additionally, Sunstone has a track record of successful IPOs and large M&A transactions within its portfolio, further solidifying its reputation in the life sciences investment space.
Q?
What are Sunstone Life Science Ventures' investment criteria?
Sunstone focuses on early-stage life science companies developing novel therapeutics, particularly those with solid in-vivo preclinical data and a well-understood mechanism of action. The firm typically invests during the pre-clinical or clinical phase I stages.
Q?
How can startups apply or pitch to Sunstone?
Startups can pitch to Sunstone Life Science Ventures by reaching out via their email at lifescience@sunstone.eu. It is advisable to include detailed information about the company, its therapeutic innovations, and any relevant data supporting the investment opportunity.
Q?
What makes Sunstone Life Science Ventures different from other VC firms?
Sunstone emphasizes a long-term partnership model, providing not only capital but also strategic guidance and support in navigating the complexities of drug development. The firm leverages its extensive network and expertise in the life sciences sector to help portfolio companies achieve their goals.
Q?
What is the geographic scope of Sunstone's investments?
Sunstone Life Science Ventures primarily focuses on investments in Europe, particularly in the UK and other key life science hubs across the continent.
Q?
What is the typical check size for investments made by Sunstone?
Sunstone typically invests in the range of Series A and B funding rounds, although specific check sizes are not disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.